---
title: "Arcus Biosciences partners with AVEO Oncology to test casdatifan-tivozanib combo in kidney cancer study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293519299.md"
description: "Arcus Biosciences has entered a clinical supply agreement with AVEO Oncology to evaluate the combination of casdatifan and tivozanib in advanced clear cell renal cell carcinoma. The randomized ARC-20 cohort study will compare casdatifan plus tivozanib against tivozanib alone. Arcus will sponsor and conduct the trial, while each company retains rights to its respective drug."
datetime: "2026-07-22T20:40:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293519299.md)
  - [en](https://longbridge.com/en/news/293519299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293519299.md)
generator: "portal-rs"
---

# Arcus Biosciences partners with AVEO Oncology to test casdatifan-tivozanib combo in kidney cancer study

-   Arcus Biosciences signed a clinical supply agreement with AVEO Oncology to test casdatifan with AVEO’s kidney cancer drug tivozanib. \* The combo will be evaluated in a new randomized ARC-20 cohort in advanced clear cell renal cell carcinoma previously treated with a HIF-2α inhibitor. \* Study design compares casdatifan with tivozanib 1.34 mg versus tivozanib 1.34 mg alone; AVEO supplies tivozanib. \* Arcus will sponsor and run the trial; each company retains development and commercial rights to its own drug. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720389288) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)

## Related News & Research

- [RCUS: Upcoming data for casdatifan may establish new benchmarks in kidney cancer treatment efficacy](https://longbridge.com/en/news/298616628.md)
- [Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News](https://longbridge.com/en/news/298502232.md)
- [RCUS: Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential](https://longbridge.com/en/news/298364956.md)
- [BUZZ-Definium rises on FDA's 'breakthrough' tag for depression drug](https://longbridge.com/en/news/298332344.md)
- [RCKT: Pivotal gene therapy trials for rare cardiomyopathies advance with strong safety and growing patient identification](https://longbridge.com/en/news/298630281.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**